Physician profile
Asim Mahmood
NPI 1144260696
$1,399.13
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $119 · 2021: $171 · 2022: $38.79 · 2023: $124 · 2024: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $202.51 | 2019-2024 | |
| Acacia Pharma INC | $180.07 | 2021-2022 | |
| Lilly USA, LLC | $138.76 | 2019-2024 | Verzenio, Jaypirca |
| Becton, Dickinson and Company | $115.36 | 2024 | Hemosphere |
| Cumberland Pharmaceuticals, INC. | $92.47 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $75.80 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $72.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.73 | 2020-2024 | Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $63.26 | 2019-2020 | |
| Edwards Lifesciences Corporation | $48.33 | 2019-2021 | |
| Tesaro, INC. | $47.09 | 2019 | |
| Seagen INC. | $39.66 | 2022-2023 | Padcev |
| Springworks Therapeutics, INC. | $34.75 | 2024 | Ogsiveo |
| Astrazeneca Pharmaceuticals LP | $32.38 | 2019-2020 | |
| Daiichi Sankyo INC. | $29.72 | 2023 | Injectafer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $28.21 | 2024 | Cleviprex |
| Blueprint Medicines Corporation | $22.35 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.19 | 2024 | Fruzaqla |
| Inari Medical, INC. | $20.72 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astellas Pharma US INC | $20.33 | 2023 | Xtandi |
| Taiho Oncology, INC. | $19.97 | 2019 | |
| Amgen INC. | $14.54 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asim Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.